NMS Labs
3701 Welsh Road, PO Box 433A, Willow Grove, PA 19090-0437
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, DABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 09/09/2011 15:06
Last Report Issued 07/20/2010 14:09

88888
Clinical Dummy reports
Attn: IT Department
3701 Welsh Road
Willow Grove, PA 19090

Patient Name 0275U-POS
Patient ID 0275U-POS
Chain 10001444
Age Not Given **Gender** Not Given

Workorder 10001444

Received 07/20/2010 14:08

Sample ID 10001444-001
Matrix Urine
Patient Name 0275U-POS
Patient ID 0275U-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
0275U Dalfampridine, Urine				
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)				
Dalfampridine	5000	ng/mL	2.0	

Synonym(s): Ampyra®; 4-Aminopyridine; p-Aminopyridine; Amino-4-pyridine; Fampridine

Dalfampridine (4-Aminopyridine) elimination is primarily through the kidneys and is nearly complete after 24 hours. Approximately 90% of the drug excreted in the urine is unchanged.